Skip To Main Content
Anju Ghangurde on Muck Rack

Anju Ghangurde

Verified
Mahārāshtra
As seen in: Scrip, The Pink Sheet, Informa, Generics Bulletin, HBW Insight, In Vivo, Citeline, Medtech Insight
Executive Editor (Asia Pacific), Scrip/Pink Sheet, @Citeline @NorstellaCo but views own; believe in karma & that moms can move mountains
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anju

Contact Anju, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FTF Gold Rush And How The US 180-Day Exclusivity Window Is Getting Crowded

|
By Anju Ghangurde Verified
| Scrip Verified
Indian firms lead Paragraph IV filings in the US as a wave of blockbuster drugs lose exclusivity between 2026-2028, but the first-to-file race is getting fiercer with over a dozen filers seen for products like AstraZeneca's Farxiga, Merck’s Bridion and BMS/Pfizer’s Eliquis.
Open in Who Shared Issue with article?

IGI CEO On The Firm’s ‘Unique’ Multispecific For Solid Tumors, Immunotherapy Over ADCs

|
By Anju Ghangurde Verified
| Scrip Verified
Ichnos Glenmark Innovation CEO Dr Lida Pacaud talks about the firm's first-in-class multispecific immune cells activator for solid tumors that takes a distinct approach on NK cell engagement and why she believes immunotherapy holds far greater power to transform cancer treatment than ADCs. IGI CEO Dr Lida Pacaud (Glenmark) “ISB 2001 is definitely my journey at Ichnos Glenmark Innovation (IGI),” said IGI CEO Dr Lida Pacaud recounting the clinical development efforts behind the firm’s...
Open in Who Shared Issue with article?

India Directs IND Route For Drugs Without Global Approval Running Local Phase III Trials

|
By Anju Ghangurde Verified
| The Pink Sheet Verified
India clarifies pathway for new drugs unapproved globally that have local Phase III studies, directing these applications to the IND division for review.
Open in Who Shared Issue with article?
See all 1,710 articles